Alector (ALEC) to Release Quarterly Earnings on Thursday

Key Points

• Alector (ALEC) is set to announce its Q2 2025 earnings on Wednesday, August 6th, with analysts predicting a loss of ($0.45) per share and revenue of $2.76 million.
• The company has recently received positive adjustments from analysts, with HC Wainwright increasing its price target from $7.00 to $10.00 and Mizuho raising their price target from $2.50 to $3.50.
• Institutional investors hold 85.83% of Alector's stock, with Strs Ohio acquiring a new stake worth approximately $126,000 during the first quarter.

Alector (NASDAQ:ALEC - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.45) per share and revenue of $2.76 million for the quarter.

Alector Stock Down 2.7%

NASDAQ ALEC traded down $0.04 on Friday, hitting $1.45. 737,122 shares of the company's stock were exchanged, compared to its average volume of 476,440. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.34 and a current ratio of 3.34. The firm's 50-day moving average price is $1.53 and its two-hundred day moving average price is $1.43. Alector has a fifty-two week low of $0.87 and a fifty-two week high of $6.37.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Alector stock. Strs Ohio purchased a new position in shares of Alector, Inc. (NASDAQ:ALEC - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 102,600 shares of the company's stock, valued at approximately $126,000. Strs Ohio owned 0.10% of Alector as of its most recent SEC filing. 85.83% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on ALEC shares. Mizuho upgraded Alector from a "neutral" rating to an "outperform" rating and boosted their target price for the stock from $2.50 to $3.50 in a research report on Monday, July 28th. HC Wainwright upped their target price on Alector from $7.00 to $10.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $4.17.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.